pharma · Lupus Nephritis · Generalized Myasthenia Gravis · AUPH
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1196 Hwy 3 South, Northfield, MN 55057, US
- Founded
- 2007
- Employees
- 81
- Programs
- 14
- Drugs
- 10
- Patents
- 7
Aurinia Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AUR-200-2024-02
Aurinia Pharmaceuticals
Generalized Myasthenia Gravis
1 trial -
Aritinercept
Aurinia Pharmaceuticals
Myasthenia Gravis, Generalized
1 trial -
Voclosporin
Aurinia Pharmaceuticals
Focal Segmental Glomerulosclerosis
1 trial -
Voclosporin
Aurinia Pharmaceuticals
Covid19
1 trial -
Voclosporin
Aurinia Pharmaceuticals
Kidney Diseases
1 trial -
Voclosporin High Dose
Aurinia Pharmaceuticals
Lupus Nephritis
1 trial -
Voclosporin Ophthalmic Solution
Aurinia Pharmaceuticals
Dry Eye
1 trial
Frequently asked questions
How many clinical projects does Aurinia Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.